Teva announces agreement on generic Pulmicort Respules patent challenge
However, their facial injuries speak volumes. Newly released research in the January/February issue of Archives of Facial Plastic Surgery, one of the JAMA/Archives journals, shows women who are victims of intimate partner violence tend to have different patterns of facial injury than women who experience facial trauma from other causes. Temple University facial plastic surgeon
Full Post: Women who suffer abuse at the hands of a loved one may not be so quick to talk about it
Teva Pharmaceutical Industries Ltd. has announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva’s U.S. generic version of AstraZeneca’s Pulmicort (Budesonide) Respules including all claims for patent infringement and damages.
Teva launched its generic budesonide respules in the U.S. on November 18, 2008. The agreement releases Teva for all past U.S. sales of its generic budesonide respules and provides that any product already shipped by Teva will remain in the market to be further distributed and dispensed. Teva will not resume shipping additional units of its budesonide respules until December 15, 2009 (or earlier based on certain contingencies) pursuant to an exclusive license for which Teva will pay AstraZeneca an undisclosed royalty.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world’s leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva’s sales are in North America and Europe.
AstraZeneca has announced it has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceuticals USA. The agreement settles the patent infringement litigation filed by AstraZeneca following Teva’s submission to the United States Food & Drug Administration of an Abbreviated New Drug
Full Post: AstraZeneca settles U.S. Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals
Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United
Full Post: Codexis announces licensing agreement with Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva’s acquisition of Barr. In connection with this approval, Teva and Barr are required to divest certain formulations of 17 generic drugs in certain specific countries with respect to which they have a product
Full Post: Teva and Barr receive European approval for acquisition
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets. As part of the settlements, the
Full Post: Barr announces agreements on Nasacort AQ, Allegra D-12 and Allegra patent challenges
Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that the U.S. Federal Trade Commission (”FTC”) has accepted the proposed consent order in connection with the pending acquisition of Barr by Teva and granted early termination of the Hart Scott Rodino waiting period. Under the consent order that has been executed by the parties
Full Post: Teva’s acquisition of Barr cleared by FTC